J&J’s Major Investment in US Manufacturing
Johnson & Johnson is investing $2 billion over the next decade to utilize a 160,000-square-foot manufacturing plant at Fujifilm Diosynth’s enormous biomanufacturing campus in Holly Springs, North Carolina, which will be operational in the fall.
Fujifilm confirmed the unification of the U.S. giant J&J in November 2023, saying that the company had invested in a large-scale manufacturing suite at the facility.
A Growing Biomanufacturing Hub
In construction since 2021 as part of a $2 billion project, FujiFilm is billing the new facility as the largest end-to-end biologics production campus in the world and anticipates staffing the plant with approximately 725 employees. In April of last year, Fujifilm took its bet a notch higher on the location, committing an additional 1.2 billion on the development of the plant and raising the expected number of employees there to 1,400 by 2031. J&J stated that its deal with Fujifilm would form approximately 120 new jobs in the state.
In April of this year, Fujifilm announced a similar deal with Regeneron, which is paying an initial rent of 3 billion to book space at the Holly Springs facility for 10 years so it can manufacture bulk drug product to supply its own commercial treatments using biologics.
Industry-Wide Trend Amid Tariff Policies
Drugmaking productions announced in the United States are made amid the Trump administration’s efforts to impose import tariffs on medicines manufactured abroad. On Thursday, the industry became even clearer when a 15% tariff on EU-produced innovative drugs was confirmed.
A number of pharma giants, both within and outside of the United States, are coming into compliance with them, such as AstraZeneca, Eli Lilly, Sanofi, and Novartis. Both firms have already announced plans to make massive investments in the U.S. in the near future.
Commitment to American Innovation
In the case of J&J, it has announced a four-year investment program in the U.S. worth a total of 55 billion, of which it will construct three new plants and develop others already present in the company network.
The company is developing the plan in conjunction with the ground-breaking announcement of a new 500,000-square-foot biologics plant in Wilson, North Carolina, about an hour drive away in Holly Springs. In October 2021, J&J announced that it would invest over $2 billion to construct the plant that will employ over 500 people and produce therapies to treat cancer, neuroscience disorders, and immunology issues.
“Of all the facilities that J&J has, most are in America more than any other country, and our presence continues to grow here in America,” said Joaquin Duato, who is its chief executive officer, in the release. “As a result of the newly signed One Big Beautiful Bill Act, we are further investing in the United States to become the main driver in healthcare innovation.”
